Gri Bio, Inc. (GRI)
NASDAQ:GRI
Want to see GRI full AI Analyst Report?
GRI Stock Chart & Stats
$0.28
-$0.06(-7.48%)
At close: 4:00 PM EST
$0.28
-$0.06(-7.48%)
Day’s Range― - ―
52-Week Range$1.97 - $80.36
Previous CloseN/A
Volume96.89K
Average Volume (3M)38.22K
Market Cap
$3.65M
Enterprise Value-$10.80M
Total Cash (Recent Filing)$11.05M
Total Debt (Recent Filing)$58.00K
Price to Earnings (P/E)―
Beta2.46
Next Earnings
Aug 19, 2026EPS Estimate
-1.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-241.87
Shares Outstanding1,770,838
10 Day Avg. Volume31,926
30 Day Avg. Volume38,224
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.11
Price to Sales (P/S)0.00
P/FCF Ratio-0.07
Enterprise Value/Market Cap-2.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.40K
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$25.00Price Target Upside8828.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.26
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Improved Balance SheetVery low reported debt and materially positive equity versus earlier years reduce near-term solvency risk and give management flexibility. Over a multi‑month horizon a cleaner balance sheet supports partnering, licensing negotiations, and program advancement without immediate distress.
Differentiated Phase 2a Clinical Data And IPRobust Phase 2a results showing symptom relief, safety and exploratory lung function/biomarker improvements strengthen the clinical case for GRI-0621. New patent filings deepen IP protection and improve long‑term partnering and regulatory pathways for pivotal development and commercialization.
Near-term Runway And Demonstrated Capital AccessReported cash and recent ATM raise extend operations into Q2 2027, giving time to advance pivotal planning and IND work. Demonstrated ability to access public markets provides a durable, if dilutive, financing channel to support program milestones over the coming 6–12 months.
Bears Say
High Cash BurnSustained negative operating and free cash flow near -$14M TTM means the business consumes capital faster than it generates it. Over the next several months this structural burn requires recurring financing, constraining investments and increasing execution risk for development programs.
Persistent Losses And Weak MarginsDeeply negative margins and widening losses show the company has not yet achieved scalable, profitable operations. This persistent unprofitability limits reinvestment, reduces resilience to trial setbacks, and makes long‑term shareholder returns dependent on successful clinical or licensing outcomes.
Dependence On External Financing / Dilution RiskThe company explicitly depends on outside capital and has recently tapped an ATM facility, evidencing dilution risk. Reliance on new funding for ongoing operations creates long‑term uncertainty and ties future progress to volatile capital markets and investor willingness to fund clinical risk.
GRI Bio News
GRI FAQ
What was Gri Bio, Inc.’s price range in the past 12 months?
Gri Bio, Inc. lowest stock price was $1.97 and its highest was $80.36 in the past 12 months.
What is Gri Bio, Inc.’s market cap?
Gri Bio, Inc.’s market cap is $3.65M.
When is Gri Bio, Inc.’s upcoming earnings report date?
Gri Bio, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 78 days.
How were Gri Bio, Inc.’s earnings last quarter?
Gri Bio, Inc. released its earnings results on May 14, 2026. The company reported -$1.61 earnings per share for the quarter, missing the consensus estimate of -$1.605 by -$0.005.
Is Gri Bio, Inc. overvalued?
According to Wall Street analysts Gri Bio, Inc.’s price is currently Undervalued.
Does Gri Bio, Inc. pay dividends?
Gri Bio, Inc. does not currently pay dividends.
What is Gri Bio, Inc.’s EPS estimate?
Gri Bio, Inc.’s EPS estimate is -1.2.
How many shares outstanding does Gri Bio, Inc. have?
Gri Bio, Inc. has 1,770,838 shares outstanding.
What happened to Gri Bio, Inc.’s price movement after its last earnings report?
Gri Bio, Inc. reported an EPS of -$1.61 in its last earnings report, missing expectations of -$1.605. Following the earnings report the stock price went down -4.867%.
Which hedge fund is a major shareholder of Gri Bio, Inc.?
Currently, no hedge funds are holding shares in GRI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Gri Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
GRI Stock 12 Month Forecast
Average Price Target
$25.00
▲(8828.57% Upside)
Technical Analysis
Ownership Overview
32.35%
Insiders
0.44% Mutual Funds
― Other Institutional Investors
67.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---